Published in Antimicrob Agents Chemother on March 18, 2013
Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis. Antimicrob Agents Chemother (2013) 1.18
Rapid cytolysis of Mycobacterium tuberculosis by faropenem, an orally bioavailable β-lactam antibiotic. Antimicrob Agents Chemother (2014) 0.99
Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus. Antimicrob Agents Chemother (2015) 0.93
In vitro susceptibility of Mycobacterium tuberculosis isolates to an oral carbapenem alone or in combination with β-lactamase inhibitors. Antimicrob Agents Chemother (2014) 0.93
Osmosensory signaling in Mycobacterium tuberculosis mediated by a eukaryotic-like Ser/Thr protein kinase. Proc Natl Acad Sci U S A (2013) 0.92
Can we prevent antimicrobial resistance by using antimicrobials better? Pathogens (2013) 0.82
Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis. Antimicrob Agents Chemother (2014) 0.81
1,4-azaindole, a potential drug candidate for treatment of tuberculosis. Antimicrob Agents Chemother (2014) 0.80
A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way. Clin Infect Dis (2016) 0.78
Syntheses and Biological Evaluations of Highly Functionalized Hydroxamate Containing and N-Methylthio Monobactams as Anti-Tuberculosis and β-Lactamase Inhibitory Agents. Medchemcomm (2015) 0.77
Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks. Clin Infect Dis (2016) 0.75
Unravelling the Secrets of Mycobacterial Cidality through the Lens of Antisense. PLoS One (2016) 0.75
Targeting Phenotypically Tolerant Mycobacterium tuberculosis. Microbiol Spectr (2017) 0.75
Mutation in an unannotated protein confers carbapenem resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2017) 0.75
Identification of mycobacterial genes involved in antibiotic sensitivity - Implications in the treatment of tuberculosis with β-lactam containing regimens. Antimicrob Agents Chemother (2017) 0.75
An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect Immun (1996) 9.21
Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J Clin Microbiol (1998) 7.84
Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am (2003) 4.16
Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science (2009) 3.73
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis (2004) 2.95
Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect Immun (2005) 2.74
A replication clock for Mycobacterium tuberculosis. Nat Med (2009) 2.49
Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate. Biochemistry (2007) 2.09
Comparative review of the carbapenems. Drugs (2007) 2.06
The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat Med (2010) 1.91
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother (2010) 1.43
Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate. Biochemistry (2008) 1.40
Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt₁ by carbapenems and cephalosporins. Antimicrob Agents Chemother (2012) 1.32
Streptomycin-starved Mycobacterium tuberculosis 18b, a drug discovery tool for latent tuberculosis. Antimicrob Agents Chemother (2012) 1.31
The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother (1989) 1.25
Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis (2012) 1.23
Meropenem-clavulanic acid shows activity against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother (2012) 1.22
Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis. Pediatr Infect Dis J (2011) 1.05
Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model. Antimicrob Agents Chemother (2012) 0.93
Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 0.84
Fast mouse PK (Fast PK): a rapid screening method to increase pharmacokinetic throughput in pre-clinical drug discovery. Eur J Pharm Sci (2012) 0.81
Molecular cloning, overexpression and biochemical characterization of hypothetical beta-lactamases of Mycobacterium tuberculosis H37Rv. J Appl Microbiol (2008) 0.80
Clinical pharmacokinetics of meropenem after the first and tenth intramuscular administration. J Antimicrob Chemother (1996) 0.79
inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science (1994) 11.22
An integrated map of the genome of the tubercle bacillus, Mycobacterium tuberculosis H37Rv, and comparison with Mycobacterium leprae. Proc Natl Acad Sci U S A (1996) 3.78
Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2003) 3.76
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis (2007) 2.74
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother (2006) 2.14
Expression of conjoined genes: another mechanism for gene regulation in eukaryotes. PLoS One (2010) 2.13
Nonalcoholic fatty liver is not associated with incident chronic kidney disease: a large histology-based comparison with healthy individuals. Eur J Gastroenterol Hepatol (2016) 2.06
Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother (2004) 1.99
Prevalence of sustained hypertension and obesity in urban and rural school going children in Ludhiana. Indian Heart J (2004) 1.57
A guinea pig model of experimental airborne tuberculosis for evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment. Tubercle (1991) 1.49
Complete genome sequences of rat and mouse segmented filamentous bacteria, a potent inducer of th17 cell differentiation. Cell Host Microbe (2011) 1.46
Influenza A/H1/N1/09 infection in patients with cirrhosis has a poor outcome: a case series. Indian J Gastroenterol (2014) 1.42
Ambulatory ST segment monitoring. Problems, pitfalls, solutions, and clinical application. Br Heart J (1980) 1.39
Thalidomide teratogenesis: evidence for a toxic arene oxide metabolite. Proc Natl Acad Sci U S A (1981) 1.38
Efflux pumps of Mycobacterium tuberculosis play a significant role in antituberculosis activity of potential drug candidates. Antimicrob Agents Chemother (2012) 1.29
Effect of once-daily atenolol on ambulatory blood pressure. Br Med J (1979) 1.22
BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuber Lung Dis (1993) 1.20
Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers. J Virol (2009) 1.19
Use of graded exercise testing in assessing the hypertensive patient. Clin Cardiol (1980) 1.18
Once daily beta-adrenoceptor blockade in hypertension: an ambulatory assessment. Br J Clin Pharmacol (1981) 1.16
Immunity to tuberculosis from the perspective of pathogenesis. Infect Immun (1989) 1.12
Exercise-induced ST segment elevation. Electrocardiographic, angiographic, and scintigraphic evaluation. Br Heart J (1980) 1.08
Propranolol LA and ambulatory blood pressure. Br J Clin Pharmacol (1980) 1.07
T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc Natl Acad Sci U S A (2011) 1.07
Rv1218c, an ABC transporter of Mycobacterium tuberculosis with implications in drug discovery. Antimicrob Agents Chemother (2010) 1.05
Myocardial ischaemia in patients with frequent angina pectoris. Br Med J (1979) 1.05
An analysis of some hypotheses related to the Chingelput bacille Calmette-Guérin trial. Clin Infect Dis (2000) 1.04
Ambulant blood pressure: reproducibility and the assessment of interventions. Clin Sci (Lond) (1980) 1.03
Fast and accurate taxonomic assignments of metagenomic sequences using MetaBin. PLoS One (2012) 1.02
Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res (2004) 1.00
Verapamil in ischaemic heart disease--quantitative assessment by serial multistage treadmill exercise. Postgrad Med J (1976) 0.99
MetaBioME: a database to explore commercially useful enzymes in metagenomic datasets. Nucleic Acids Res (2009) 0.98
Molecular Characterization of Geographically Different Banana bunchy top virus Isolates in India. Indian J Virol (2011) 0.97
Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo. J Med Chem (2013) 0.97
MAAP: malarial adhesins and adhesin-like proteins predictor. Proteins (2008) 0.95
Slow channel inhibitors verapamil and nifedipine in the management of hypertension. J Cardiovasc Pharmacol (1982) 0.93
Aminonaphthoquinones--a novel class of compounds with potent antimalarial activity against Plasmodium falciparum. Pharmacol Res (2001) 0.93
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis. J Med Chem (2014) 0.93
Effect of coadministration of moxifloxacin and rifampin on Mycobacterium tuberculosis in a murine aerosol infection model. Antimicrob Agents Chemother (2012) 0.93
Aminopyrazinamides: novel and specific GyrB inhibitors that kill replicating and nonreplicating Mycobacterium tuberculosis. ACS Chem Biol (2012) 0.90
Abundance of dinucleotide repeats and gene expression are inversely correlated: a role for gene function in addition to intron length. Physiol Genomics (2007) 0.90
Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activity. J Med Chem (2014) 0.89
Animal models for experimental tuberculosis. Clin Infect Dis (2000) 0.89
Effect of labetalol on continuous ambulatory blood pressure. Br J Clin Pharmacol (1979) 0.89
Treatment of type II endoleaks with a novel polyurethane thrombogenic foam: induction of endoleak thrombosis and elimination of intra-aneurysmal pressure in the canine model. J Vasc Surg (2005) 0.89
Production of tannase under solid-state fermentation and its application in detannification of guava juice. Prep Biochem Biotechnol (2014) 0.88
Comparison of results in endovascular interventions for infrainguinal lesions: claudication versus critical limb ischemia. Am Surg (2005) 0.88
An anti-inflammatory role of VEGFR2/Src kinase inhibitor in herpes simplex virus 1-induced immunopathology. J Virol (2011) 0.88
Blood pressure circadian rhythm in essential hypertension. Clin Sci Mol Med Suppl (1978) 0.87
Sudden death during ambulatory monitoring. Br Med J (1979) 0.87
Electrical impedance cardiogram in derivation of systolic time intervals. Br Heart J (1978) 0.87
Optimization of pyrrolamides as mycobacterial GyrB ATPase inhibitors: structure-activity relationship and in vivo efficacy in a mouse model of tuberculosis. Antimicrob Agents Chemother (2013) 0.87
A kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli. Adv Appl Bioinform Chem (2010) 0.87
Eberconazole--pharmacological and clinical review. Indian J Dermatol Venereol Leprol (2012) 0.86
Syncope in a middle aged male due to acute rheumatic fever. Indian Heart J (2005) 0.86
Effects of high altitude hypoxia on left ventricular systolic time intervals in man. Br Heart J (1975) 0.86
Traumatic spinal cord injuries. Lancet (2011) 0.86
Internal and external rotation of the shoulder: effects of plane, end-range determination, and scapular motion. J Shoulder Elbow Surg (2005) 0.85
Changes in transthoracic electrical impedance during submaximal treadmill exercise in patients with ischemic heart disease--A preliminary report. Am Heart J (1976) 0.85
Cancer chemopreventive activity of synthetic colorants used in foods, pharmaceuticals and cosmetic preparations. Cancer Lett (1998) 0.85
Biological roles and functional mechanisms of arenavirus Z protein in viral replication. J Virol (2012) 0.85
On-line digital computer quantitated ST segment response to sub-maximal tread mill exercise. J Assoc Physicians India (1975) 0.85
Correlation of ultrasonographic parameters with serum creatinine in chronic kidney disease. J Clin Imaging Sci (2013) 0.85
Percutaneous endovascular treatment for chronic limb ischemia. Ann Vasc Surg (2005) 0.84
Significance of tall precordial T waves: an electrocardiographic study in Indians. Chest (1973) 0.84
Usefulness of 16S rDNA sequencing for the diagnosis of infective endocarditis caused by Corynebacterium diphtheriae. J Med Microbiol (2012) 0.84
A distributed model of carbohydrate transport and metabolism in the liver during rest and high-intensity exercise. Ann Biomed Eng (2006) 0.84
Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in Mycobacterium tuberculosis. Antimicrob Agents Chemother (2013) 0.84
Biochemical basis of heart function. X. Reduction in the Na+-K+-stimulated ATPase activity in failing rat heart due to hypoxia. Can J Physiol Pharmacol (1973) 0.84
Transthoracic electrical impedance in cases of high-altitude hypoxia. Br Med J (1974) 0.84
Avian rotavirus enteritis - an updated review. Vet Q (2015) 0.84
Counting probability distributions: differential geometry and model selection. Proc Natl Acad Sci U S A (2000) 0.83
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents. J Med Chem (2014) 0.83
4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity. J Med Chem (2014) 0.82
Lead optimization of 1,4-azaindoles as antimycobacterial agents. J Med Chem (2014) 0.82
N-aryl-2-aminobenzimidazoles: novel, efficacious, antimalarial lead compounds. J Med Chem (2014) 0.82